TY - BOOK AU - Fehr, A. R. AU - Perlman, S. PY - 2015 DA - 2015// TI - Coronaviruses: an overview of their replication and pathogenesis. Coronaviruses PB - Springer CY - Berlin UR - https://doi.org/10.1007/978-1-4939-2438-7_1 DO - 10.1007/978-1-4939-2438-7_1 ID - Fehr2015 ER - TY - JOUR AU - Zaki, A. M. AU - Boheemen, S. AU - Bestebroer, T. M. AU - Osterhaus, A. D. AU - Fouchier, R. A. PY - 2012 DA - 2012// TI - Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia JO - N Engl J Med VL - 367 UR - https://doi.org/10.1056/NEJMoa1211721 DO - 10.1056/NEJMoa1211721 ID - Zaki2012 ER - TY - JOUR AU - Su, S. AU - Wong, G. AU - Shi, W. AU - Liu, J. AU - Lai, A. C. AU - Zhou, J. PY - 2016 DA - 2016// TI - Epidemiology, genetic recombination, and pathogenesis of coronaviruses JO - Trends Microbiol VL - 24 UR - https://doi.org/10.1016/j.tim.2016.03.003 DO - 10.1016/j.tim.2016.03.003 ID - Su2016 ER - TY - STD TI - WHO. Coronavirus disease (COVID-2019) situation reports, https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports; 2020. UR - https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports ID - ref4 ER - TY - STD TI - Zhang Y-Z. Novel 2019 coronavirus genome. Virological 2020. Accessed 21 Jan 2020. ID - ref5 ER - TY - JOUR AU - Groot, R. J. AU - Baker, S. AU - Baric, R. AU - Enjuanes, L. AU - Gorbalenya, A. AU - Holmes, K. PY - 2012 DA - 2012// TI - Family coronaviridae JO - Virus Taxon. VL - 2012 ID - Groot2012 ER - TY - STD TI - Perlman S. Another decade, another coronavirus. Mass Medical Soc; 2020. ID - ref7 ER - TY - JOUR AU - Wang, N. AU - Li, S. -. Y. AU - Yang, X. -. L. AU - Huang, H. -. M. AU - Zhang, Y. -. J. AU - Guo, H. PY - 2018 DA - 2018// TI - Serological evidence of bat SARS-related coronavirus infection in humans, China JO - Virol Sinica VL - 33 UR - https://doi.org/10.1007/s12250-018-0012-7 DO - 10.1007/s12250-018-0012-7 ID - Wang2018 ER - TY - STD TI - HongKong. Centre for Health Protection, Department of Health—Severe Respiratory Disease associated with a Novel Infectious Agent. 2020. https://www.chp.gov.hk/en/features/102465.html. UR - https://www.chp.gov.hk/en/features/102465.html ID - ref9 ER - TY - JOUR AU - Jin, Y. -. H. AU - Cai, L. AU - Cheng, Z. -. S. AU - Cheng, H. AU - Deng, T. AU - Fan, Y. -. P. PY - 2020 DA - 2020// TI - A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version) JO - Milit Med Res VL - 7 UR - https://doi.org/10.1186/s40779-020-0233-6 DO - 10.1186/s40779-020-0233-6 ID - Jin2020 ER - TY - JOUR AU - Huang, C. AU - Wang, Y. AU - Li, X. AU - Ren, L. AU - Zhao, J. AU - Hu, Y. PY - 2020 DA - 2020// TI - Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China JO - Lancet. VL - 395 UR - https://doi.org/10.1016/S0140-6736(20)30183-5 DO - 10.1016/S0140-6736(20)30183-5 ID - Huang2020 ER - TY - JOUR AU - Chen, L. AU - Liu, W. AU - Zhang, Q. AU - Xu, K. AU - Ye, G. AU - Wu, W. PY - 2020 DA - 2020// TI - RNA based mNGS approach identifies a novel human coronavirus from two individual pneumonia cases in 2019 Wuhan outbreak JO - Emerg Microbes Infect VL - 9 UR - https://doi.org/10.1080/22221751.2020.1725399 DO - 10.1080/22221751.2020.1725399 ID - Chen2020 ER - TY - JOUR AU - Shi, M. AU - Zhang, Y. -. Z. AU - Holmes, E. C. PY - 2018 DA - 2018// TI - Meta-transcriptomics and the evolutionary biology of RNA viruses JO - Virus Res VL - 243 UR - https://doi.org/10.1016/j.virusres.2017.10.016 DO - 10.1016/j.virusres.2017.10.016 ID - Shi2018 ER - TY - STD TI - Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nature Publishing Group; 2020. ID - ref14 ER - TY - JOUR AU - Lu, D. -. Y. AU - Lu, T. -. R. AU - Wu, H. -. Y. PY - 2012 DA - 2012// TI - Avian flu; pathogenesis and therapy JO - Anti-Infect Agents VL - 10 UR - https://doi.org/10.2174/2211362611208020124 DO - 10.2174/2211362611208020124 ID - Lu2012 ER - TY - STD TI - Luo L, Jiang J, Wang C, Fitzgerald M, Hu W, Zhou Y, et al. Analysis on herbal medicines utilized for treatment of COVID-19. Acta Pharmaceutica Sinica B. 2020. ID - ref16 ER - TY - STD TI - Ma L-L, Ge M, Wang H-Q, Yin J-Q, Jiang J-D, Li Y-H. Antiviral activities of several oral traditional Chinese medicines against influenza viruses. Evid Based Compl Altern Med. 2015;2015. ID - ref17 ER - TY - STD TI - Lin LL, Shan JJ, Xie T, Xu JY, Shen CS, Di LQ, et al. Application of traditional Chinese medical herbs in prevention and treatment of respiratory syncytial virus. Evidence-Based Complementary and Alternative Medicine 2016;2016. ID - ref18 ER - TY - JOUR AU - Eng, Y. S. AU - Lee, C. H. AU - Lee, W. C. AU - Huang, C. C. AU - Chang, J. S. PY - 2019 DA - 2019// TI - Unraveling the molecular mechanism of traditional chinese medicine: formulas against acute airway viral infections as examples JO - Molecules VL - 24 UR - https://doi.org/10.3390/molecules24193505 DO - 10.3390/molecules24193505 ID - Eng2019 ER - TY - JOUR AU - Pu, X. AU - Ren, J. AU - Ma, X. AU - Liu, L. AU - Yu, S. AU - Li, X. PY - 2015 DA - 2015// TI - Polyphylla saponin I has antiviral activity against influenza A virus JO - Int J Clin Exp Med VL - 8 ID - Pu2015 ER - TY - JOUR AU - Song, J. H. AU - Choi, H. J. AU - Song, H. H. AU - Hong, E. H. AU - Lee, B. R. AU - Oh, S. R. PY - 2014 DA - 2014// TI - Antiviral activity of ginsenosides against coxsackievirus B3, enterovirus 71, and human rhinovirus 3 JO - J Ginseng Res VL - 38 UR - https://doi.org/10.1016/j.jgr.2014.04.003 DO - 10.1016/j.jgr.2014.04.003 ID - Song2014 ER - TY - JOUR AU - Kang, L. J. AU - Choi, Y. J. AU - Lee, S. G. PY - 2013 DA - 2013// TI - Stimulation of TRAF6/TAK1 degradation and inhibition of JNK/AP-1 signalling by ginsenoside Rg3 attenuates hepatitis B virus replication JO - Int J Biochem Cell Biol VL - 45 UR - https://doi.org/10.1016/j.biocel.2013.08.016 DO - 10.1016/j.biocel.2013.08.016 ID - Kang2013 ER - TY - JOUR AU - Kim, S. J. AU - Jang, J. Y. AU - Kim, E. J. AU - Cho, E. K. AU - Ahn, D. G. AU - Kim, C. PY - 2017 DA - 2017// TI - Ginsenoside Rg3 restores hepatitis C virus–induced aberrant mitochondrial dynamics and inhibits virus propagation JO - Hepatology VL - 66 UR - https://doi.org/10.1002/hep.29177 DO - 10.1002/hep.29177 ID - Kim2017 ER - TY - JOUR AU - Cinatl, J. AU - Morgenstern, B. AU - Bauer, G. AU - Chandra, P. AU - Rabenau, H. AU - Doerr, H. W. PY - 2003 DA - 2003// TI - Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus JO - Lancet VL - 361 UR - https://doi.org/10.1016/S0140-6736(03)13615-X DO - 10.1016/S0140-6736(03)13615-X ID - Cinatl2003 ER - TY - JOUR AU - Feng Yeh, C. AU - Wang, K. C. AU - Chiang, L. C. AU - Shieh, D. E. AU - Yen, M. H. AU - San, C. h. a. n. g. J. PY - 2013 DA - 2013// TI - Water extract of licorice had anti-viral activity against human respiratory syncytial virus in human respiratory tract cell lines JO - J Ethnopharmacol VL - 148 UR - https://doi.org/10.1016/j.jep.2013.04.040 DO - 10.1016/j.jep.2013.04.040 ID - Feng Yeh2013 ER - TY - JOUR AU - Chen, X. AU - Wang, Z. AU - Yang, Z. AU - Wang, J. AU - Xu, Y. AU - Tan, R. X. PY - 2011 DA - 2011// TI - Houttuynia cordata blocks HSV infection through inhibition of NF-kappaB activation JO - Antiviral Res VL - 92 UR - https://doi.org/10.1016/j.antiviral.2011.09.005 DO - 10.1016/j.antiviral.2011.09.005 ID - Chen2011 ER - TY - JOUR AU - Lau, K. M. AU - Lee, K. M. AU - Koon, C. M. AU - Cheung, C. S. AU - Lau, C. P. AU - Ho, H. M. PY - 2008 DA - 2008// TI - Immunomodulatory and anti-SARS activities of Houttuynia cordata JO - J Ethnopharmacol VL - 118 UR - https://doi.org/10.1016/j.jep.2008.03.018 DO - 10.1016/j.jep.2008.03.018 ID - Lau2008 ER - TY - JOUR AU - Nayak, M. K. AU - Agrawal, A. S. AU - Bose, S. AU - Naskar, S. AU - Bhowmick, R. AU - Chakrabarti, S. PY - 2014 DA - 2014// TI - Antiviral activity of baicalin against influenza virus H1N1-pdm09 is due to modulation of NS1-mediated cellular innate immune responses JO - J Antimicrob Chemother VL - 69 UR - https://doi.org/10.1093/jac/dkt534 DO - 10.1093/jac/dkt534 ID - Nayak2014 ER - TY - JOUR AU - Yu, W. Y. AU - Li, L. AU - Wu, F. AU - Zhang, H. H. AU - Fang, J. AU - Zhong, Y. S. PY - 2020 DA - 2020// TI - Moslea Herba flavonoids alleviated influenza A virus-induced pulmonary endothelial barrier disruption via suppressing NOX4/NF-kappaB/MLCK pathway JO - J Ethnopharmacol VL - 253 UR - https://doi.org/10.1016/j.jep.2020.112641 DO - 10.1016/j.jep.2020.112641 ID - Yu2020 ER - TY - JOUR AU - Li, C. AU - Wang, P. AU - Zhang, L. AU - Li, M. AU - Lei, X. AU - Liu, S. PY - 2018 DA - 2018// TI - Efficacy and safety of Xuebijing injection (a Chinese patent) for sepsis: a meta-analysis of randomized controlled trials JO - J Ethnopharmacol VL - 224 UR - https://doi.org/10.1016/j.jep.2018.05.043 DO - 10.1016/j.jep.2018.05.043 ID - Li2018 ER - TY - JOUR AU - Qi, F. AU - Liang, Z. X. AU - She, D. Y. AU - Yan, G. T. AU - Chen, L. A. PY - 2011 DA - 2011// TI - A clinical study on the effects and mechanism of xuebijing injection in severe pneumonia patients JO - J Tradit Chin Med VL - 31 UR - https://doi.org/10.1016/S0254-6272(11)60011-3 DO - 10.1016/S0254-6272(11)60011-3 ID - Qi2011 ER - TY - JOUR AU - Song, Y. AU - Yao, C. AU - Yao, Y. AU - Han, H. AU - Zhao, X. AU - Yu, K. PY - 2019 DA - 2019// TI - XueBiJing injection versus placebo for critically ill patients with severe community-acquired pneumonia: a randomized controlled trial JO - Crit Care Med VL - 47 UR - https://doi.org/10.1097/CCM.0000000000003842 DO - 10.1097/CCM.0000000000003842 ID - Song2019 ER - TY - JOUR AU - Li, Q. AU - Li, Z. Y. AU - Zhang, J. AU - Guo, W. N. AU - Xu, X. M. AU - Sun, F. X. PY - 2019 DA - 2019// TI - Xiyanping Plus Azithromycin Chemotherapy in Pediatric Patients with Mycoplasma pneumoniae Pneumonia: a Systematic Review and Meta-Analysis of Efficacy and Safety JO - Evid Based Compl Alternat Med VL - 2019 ID - Li2019 ER - TY - JOUR AU - Zhang, Q. AU - Li, C. S. AU - Wang, S. AU - Gu, W. PY - 2016 DA - 2016// TI - Effects of Chinese medicine shen-fu injection on the expression of inflammatory cytokines and complements during post-resuscitation immune dysfunction in a porcine model JO - Chin J Integr Med VL - 22 UR - https://doi.org/10.1007/s11655-014-1857-8 DO - 10.1007/s11655-014-1857-8 ID - Zhang2016 ER - TY - JOUR AU - Liu, X. AU - Ai, F. AU - Li, H. AU - Xu, Q. AU - Mei, L. AU - Miao, J. PY - 2019 DA - 2019// TI - Anti-Inflammatory Effects of Shenfu Injection against Acute Lung Injury through Inhibiting HMGB1-NF-kappaB Pathway in a Rat Model of Endotoxin Shock JO - Evid Based Complement Alternat Med VL - 2019 ID - Liu2019 ER - TY - JOUR AU - Ma, R. AU - Ma, X. AU - Wen, J. AU - Wang, J. AU - Xie, Q. AU - Chen, N. PY - 2018 DA - 2018// TI - Preclinical evidence and mechanism of Xingnaojing injection for cerebral ischemia: a systematic review and meta-analysis of animal studies JO - Evid Based Complement Alternat Med VL - 2018 ID - Ma2018 ER - TY - JOUR AU - Wong, C. K. AU - Lam, C. W. AU - Wu, A. K. AU - Ip, W. K. AU - Lee, N. L. AU - Chan, I. H. PY - 2004 DA - 2004// TI - Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome JO - Clin Exp Immunol VL - 136 UR - https://doi.org/10.1111/j.1365-2249.2004.02415.x DO - 10.1111/j.1365-2249.2004.02415.x ID - Wong2004 ER - TY - STD TI - Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. for the China Novel Coronavirus Investigating and Research Team (2020) A novel Coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020. ID - ref38 ER - TY - STD TI - Blanco-Melo D, Nilsson-Payant BE, Liu W-C, Uhl S, Hoagland D, Møller R, et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell. 2020. ID - ref39 ER - TY - STD TI - Liu K, Fang Y-Y, Deng Y, Liu W, Wang M-F, Ma J-P, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J. 2020. ID - ref40 ER - TY - JOUR AU - Broek, M. F. AU - Muller, U. AU - Huang, S. AU - Zinkernagel, R. M. AU - Aguet, M. PY - 1995 DA - 1995// TI - Immune defence in mice lacking type I and/or type II interferon receptors JO - Immunol Rev VL - 148 UR - https://doi.org/10.1111/j.1600-065X.1995.tb00090.x DO - 10.1111/j.1600-065X.1995.tb00090.x ID - Broek1995 ER - TY - JOUR AU - Teijaro, J. R. PY - 2016 DA - 2016// TI - Type I interferons in viral control and immune regulation JO - Current opinion in virology VL - 16 UR - https://doi.org/10.1016/j.coviro.2016.01.001 DO - 10.1016/j.coviro.2016.01.001 ID - Teijaro2016 ER - TY - JOUR AU - Cook, L. E. AU - Locke, M. C. AU - Young, A. R. AU - Monte, K. AU - Hedberg, M. L. AU - Shimak, R. M. PY - 2019 DA - 2019// TI - Distinct roles of interferon alpha and beta in controlling chikungunya virus replication and modulating neutrophil-mediated inflammation JO - J Virol VL - 94 UR - https://doi.org/10.1128/JVI.00841-19 DO - 10.1128/JVI.00841-19 ID - Cook2019 ER - TY - JOUR AU - Mordstein, M. AU - Neugebauer, E. AU - Ditt, V. AU - Jessen, B. AU - Rieger, T. AU - Falcone, V. PY - 2010 DA - 2010// TI - Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections JO - J Virol VL - 84 UR - https://doi.org/10.1128/JVI.00272-10 DO - 10.1128/JVI.00272-10 ID - Mordstein2010 ER - TY - JOUR AU - Lee, S. AU - Baldridge, M. T. PY - 2017 DA - 2017// TI - Interferon-lambda: a potent regulator of intestinal viral infections JO - Front Immunol VL - 8 UR - https://doi.org/10.3389/fimmu.2017.00749 DO - 10.3389/fimmu.2017.00749 ID - Lee2017 ER - TY - JOUR AU - Davidson, S. AU - McCabe, T. M. AU - Crotta, S. AU - Gad, H. H. AU - Hessel, E. M. AU - Beinke, S. PY - 2016 DA - 2016// TI - IFNlambda is a potent anti-influenza therapeutic without the inflammatory side effects of IFNalpha treatment JO - EMBO Mol Med VL - 8 UR - https://doi.org/10.15252/emmm.201606413 DO - 10.15252/emmm.201606413 ID - Davidson2016 ER - TY - JOUR AU - Ramos, E. L. PY - 2010 DA - 2010// TI - Preclinical and clinical development of pegylated interferon-lambda 1 in chronic hepatitis C JO - J Interferon Cytokine Res VL - 30 UR - https://doi.org/10.1089/jir.2010.0066 DO - 10.1089/jir.2010.0066 ID - Ramos2010 ER - TY - BOOK AU - Dipiro, J. T. AU - Talbert, R. L. AU - Yee, G. C. AU - Matzke, G. R. AU - Wells, B. G. AU - Posey, L. M. PY - 2014 DA - 2014// TI - Pharmacotherapy: a pathophysiologic approach PB - McGraw-Hill Medical CY - New York ID - Dipiro2014 ER - TY - JOUR AU - Chehimi, J. AU - Trinchieri, G. PY - 1994 DA - 1994// TI - Interleukin-12: a bridge between innate resistance and adaptive immunity with a role in infection and acquired immunodeficiency JO - J Clin Immunol VL - 14 UR - https://doi.org/10.1007/BF01533364 DO - 10.1007/BF01533364 ID - Chehimi1994 ER - TY - JOUR AU - Schurich, A. AU - Pallett, L. J. AU - Lubowiecki, M. AU - Singh, H. D. AU - Gill, U. S. AU - Kennedy, P. T. PY - 2013 DA - 2013// TI - The third signal cytokine IL-12 rescues the anti-viral function of exhausted HBV-specific CD8 T cells JO - PLoS Pathog VL - 9 UR - https://doi.org/10.1371/journal.ppat.1003208 DO - 10.1371/journal.ppat.1003208 ID - Schurich2013 ER - TY - JOUR AU - Garg, A. AU - Rawat, P. AU - Spector, S. A. PY - 2015 DA - 2015// TI - Interleukin 23 produced by myeloid dendritic cells contributes to T-cell dysfunction in HIV type 1 infection by inducing SOCS1 expression JO - J Infect Dis VL - 211 UR - https://doi.org/10.1093/infdis/jiu523 DO - 10.1093/infdis/jiu523 ID - Garg2015 ER - TY - JOUR AU - Aparicio-Siegmund, S. AU - Garbers, C. PY - 2015 DA - 2015// TI - The biology of interleukin-27 reveals unique pro-and anti-inflammatory functions in immunity JO - Cytokine Growth Factor Rev VL - 26 UR - https://doi.org/10.1016/j.cytogfr.2015.07.008 DO - 10.1016/j.cytogfr.2015.07.008 ID - Aparicio-Siegmund2015 ER - TY - JOUR AU - Bastian, D. AU - Wu, Y. AU - Betts, B. C. AU - Yu, X. Z. PY - 2019 DA - 2019// TI - The IL-12 cytokine and receptor family in graft-vs-host disease JO - Front Immunol VL - 10 UR - https://doi.org/10.3389/fimmu.2019.00988 DO - 10.3389/fimmu.2019.00988 ID - Bastian2019 ER - TY - JOUR AU - Heikkila, O. AU - Nygardas, M. AU - Paavilainen, H. AU - Ryodi, E. AU - Hukkanen, V. PY - 2016 DA - 2016// TI - Interleukin-27 inhibits herpes simplex virus type 1 infection by activating STAT1 and 3, interleukin-6, and chemokines IP-10 and MIG JO - J Interferon Cytokine Res VL - 36 UR - https://doi.org/10.1089/jir.2016.0015 DO - 10.1089/jir.2016.0015 ID - Heikkila2016 ER - TY - JOUR AU - Shao, X. AU - Ma, J. AU - Jia, S. AU - Yang, L. AU - Wang, W. AU - Jin, Z. PY - 2017 DA - 2017// TI - Interleukin-35 suppresses antiviral immune response in chronic hepatitis B virus infection JO - Front Cell Infect Microbiol VL - 7 UR - https://doi.org/10.3389/fcimb.2017.00472 DO - 10.3389/fcimb.2017.00472 ID - Shao2017 ER - TY - JOUR AU - Wang, L. AU - Zhu, S. AU - Xu, G. AU - Feng, J. AU - Han, T. AU - Zhao, F. PY - 2016 DA - 2016// TI - Gene expression and antiviral activity of interleukin-35 in response to influenza A virus infection JO - J Biol Chem VL - 291 UR - https://doi.org/10.1074/jbc.M115.693101 DO - 10.1074/jbc.M115.693101 ID - Wang2016 ER - TY - JOUR AU - Gosselin, J. AU - TomoIu, A. AU - Gallo, R. C. AU - Flamand, L. PY - 1999 DA - 1999// TI - Interleukin-15 as an activator of natural killer cell-mediated antiviral response JO - Blood VL - 94 UR - https://doi.org/10.1182/blood.V94.12.4210.424k07_4210_4219 DO - 10.1182/blood.V94.12.4210.424k07_4210_4219 ID - Gosselin1999 ER - TY - JOUR AU - Mueller, Y. M. AU - Bojczuk, P. M. AU - Halstead, E. S. AU - Kim, A. H. AU - Witek, J. AU - Altman, J. D. PY - 2003 DA - 2003// TI - IL-15 enhances survival and function of HIV-specific CD8+ T cells JO - Blood VL - 101 UR - https://doi.org/10.1182/blood-2002-07-1957 DO - 10.1182/blood-2002-07-1957 ID - Mueller2003 ER - TY - JOUR AU - Vahedi, F. AU - Lee, A. J. AU - Collins, S. E. AU - Chew, M. V. AU - Lusty, E. AU - Chen, B. PY - 2019 DA - 2019// TI - IL-15 and IFN-gamma signal through the ERK pathway to inhibit HCV replication, independent of type I IFN signaling JO - Cytokine VL - 124 UR - https://doi.org/10.1016/j.cyto.2018.06.006 DO - 10.1016/j.cyto.2018.06.006 ID - Vahedi2019 ER - TY - JOUR AU - Xu, X. Q. AU - Liu, Y. AU - Zhang, B. AU - Liu, H. AU - Shao, D. D. AU - Liu, J. B. PY - 2019 DA - 2019// TI - IL-22 suppresses HSV-2 replication in human cervical epithelial cells JO - Cytokine VL - 123 UR - https://doi.org/10.1016/j.cyto.2019.154776 DO - 10.1016/j.cyto.2019.154776 ID - Xu2019 ER - TY - JOUR AU - Hernandez, P. P. AU - Mahlakoiv, T. AU - Yang, I. AU - Schwierzeck, V. AU - Nguyen, N. AU - Guendel, F. PY - 2015 DA - 2015// TI - Interferon-lambda and interleukin 22 act synergistically for the induction of interferon-stimulated genes and control of rotavirus infection JO - Nat Immunol VL - 16 UR - https://doi.org/10.1038/ni.3180 DO - 10.1038/ni.3180 ID - Hernandez2015 ER - TY - JOUR AU - Guabiraba, R. AU - Besnard, A. G. AU - Marques, R. E. AU - Maillet, I. AU - Fagundes, C. T. AU - Conceicao, T. M. PY - 2013 DA - 2013// TI - IL-22 modulates IL-17A production and controls inflammation and tissue damage in experimental dengue infection JO - Eur J Immunol VL - 43 UR - https://doi.org/10.1002/eji.201243229 DO - 10.1002/eji.201243229 ID - Guabiraba2013 ER - TY - JOUR AU - Gimeno Brias, S. AU - Stack, G. AU - Stacey, M. A. AU - Redwood, A. J. AU - Humphreys, I. R. PY - 2016 DA - 2016// TI - The role of IL-22 in viral infections: paradigms and paradoxes JO - Front Immunol VL - 7 UR - https://doi.org/10.3389/fimmu.2016.00211 DO - 10.3389/fimmu.2016.00211 ID - Gimeno Brias2016 ER - TY - JOUR AU - Zumla, A. AU - Chan, J. F. AU - Azhar, E. I. AU - Hui, D. S. AU - Yuen, K. -. Y. PY - 2016 DA - 2016// TI - Coronaviruses—drug discovery and therapeutic options JO - Nat Rev Drug Discov VL - 15 UR - https://doi.org/10.1038/nrd.2015.37 DO - 10.1038/nrd.2015.37 ID - Zumla2016 ER - TY - STD TI - Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet 2020. ID - ref65 ER - TY - JOUR AU - Xie, J. AU - Zhang, S. AU - Hu, Y. AU - Li, D. AU - Cui, J. AU - Xue, J. PY - 2014 DA - 2014// TI - Regulatory roles of c-jun in H5N1 influenza virus replication and host inflammation JO - BBA Mol Basis Dis. VL - 1842 UR - https://doi.org/10.1016/j.bbadis.2014.04.017 DO - 10.1016/j.bbadis.2014.04.017 ID - Xie2014 ER - TY - JOUR AU - Börgeling, Y. AU - Schmolke, M. AU - Viemann, D. AU - Nordhoff, C. AU - Roth, J. AU - Ludwig, S. PY - 2014 DA - 2014// TI - Inhibition of p38 mitogen-activated protein kinase impairs influenza virus-induced primary and secondary host gene responses and protects mice from lethal H5N1 infection JO - J Biol Chem VL - 289 UR - https://doi.org/10.1074/jbc.M113.469239 DO - 10.1074/jbc.M113.469239 ID - Börgeling2014 ER - TY - JOUR AU - Yángüez, E. AU - Hunziker, A. AU - Dobay, M. P. AU - Yildiz, S. AU - Schading, S. AU - Elshina, E. PY - 2018 DA - 2018// TI - Phosphoproteomic-based kinase profiling early in influenza virus infection identifies GRK2 as antiviral drug target JO - Nat Commun VL - 9 UR - https://doi.org/10.1038/s41467-018-06119-y DO - 10.1038/s41467-018-06119-y ID - Yángüez2018 ER - TY - JOUR AU - Xia, C. AU - Seo, Y. -. J. AU - Studstill, C. J. AU - Vijayan, M. AU - Wolf, J. J. AU - Hahm, B. PY - 2018 DA - 2018// TI - Transient inhibition of sphingosine kinases confers protection to influenza A virus infected mice JO - Antiviral Res VL - 158 UR - https://doi.org/10.1016/j.antiviral.2018.08.010 DO - 10.1016/j.antiviral.2018.08.010 ID - Xia2018 ER - TY - JOUR AU - Salazar, G. AU - Zhang, N. AU - Fu, T. AU - An, Z. PY - 2017 DA - 2017// TI - Antibody therapies for the prevention and treatment of viral infections JO - NPJ Vaccin VL - 2 UR - https://doi.org/10.1038/s41541-017-0019-3 DO - 10.1038/s41541-017-0019-3 ID - Salazar2017 ER - TY - JOUR AU - Fukushi, S. AU - Fukuma, A. AU - Kurosu, T. AU - Watanabe, S. AU - Shimojima, M. AU - Shirato, K. PY - 2018 DA - 2018// TI - Characterization of novel monoclonal antibodies against the MERS-coronavirus spike protein and their application in species-independent antibody detection by competitive ELISA JO - J Virol Methods VL - 251 UR - https://doi.org/10.1016/j.jviromet.2017.10.008 DO - 10.1016/j.jviromet.2017.10.008 ID - Fukushi2018 ER - TY - JOUR AU - Meulen, J. AU - Brink, E. N. AU - Poon, L. L. AU - Marissen, W. E. AU - Leung, C. S. AU - Cox, F. PY - 2006 DA - 2006// TI - Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants JO - PLoS Med VL - 3 ID - Meulen2006 ER - TY - JOUR AU - Chames, P. AU - Regenmortel, M. AU - Weiss, E. AU - Baty, D. PY - 2009 DA - 2009// TI - Therapeutic antibodies: successes, limitations and hopes for the future JO - Br J Pharmacol VL - 157 UR - https://doi.org/10.1111/j.1476-5381.2009.00190.x DO - 10.1111/j.1476-5381.2009.00190.x ID - Chames2009 ER - TY - JOUR AU - Rosendahl Huber, S. AU - Beek, J. AU - Jonge, J. AU - Luytjes, W. AU - Baarle, D. PY - 2014 DA - 2014// TI - T cell responses to viral infections–opportunities for peptide vaccination JO - Front Immunol VL - 5 UR - https://doi.org/10.3389/fimmu.2014.00171 DO - 10.3389/fimmu.2014.00171 ID - Rosendahl Huber2014 ER - TY - STD TI - Bojin F, Gavriliuc O, Margineanu M-B, Paunescu V. Design of an epitope-based synthetic long peptide vaccine to counteract the novel China Coronavirus (2019-nCoV). 2020. ID - ref75 ER - TY - JOUR AU - Skalickova, S. AU - Heger, Z. AU - Krejcova, L. AU - Pekarik, V. AU - Bastl, K. AU - Janda, J. PY - 2015 DA - 2015// TI - Perspective of use of antiviral peptides against influenza virus JO - Viruses VL - 7 UR - https://doi.org/10.3390/v7102883 DO - 10.3390/v7102883 ID - Skalickova2015 ER - TY - STD TI - Liu W, Morse JS, Lalonde T, Xu S. Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019‐nCoV. Chembiochem. 2020. ID - ref77 ER - TY - JOUR AU - Haggag, Y. A. AU - Donia, A. A. AU - Osman, M. A. AU - El-Gizawy, S. A. PY - 2018 DA - 2018// TI - Peptides as drug candidates: limitations and recent development perspectives JO - Biomed J VL - 1 ID - Haggag2018 ER - TY - JOUR AU - Kaufmann, S. H. AU - Dorhoi, A. AU - Hotchkiss, R. S. AU - Bartenschlager, R. PY - 2018 DA - 2018// TI - Host-directed therapies for bacterial and viral infections JO - Nat Rev Drug Discov VL - 17 UR - https://doi.org/10.1038/nrd.2017.162 DO - 10.1038/nrd.2017.162 ID - Kaufmann2018 ER - TY - JOUR AU - Arabi, Y. M. AU - Fowler, R. AU - Hayden, F. G. PY - 2020 DA - 2020// TI - Critical care management of adults with community-acquired severe respiratory viral infection JO - Intens Care Med VL - 1 ID - Arabi2020 ER - TY - JOUR AU - Gao, H. -. N. AU - Lu, H. -. Z. AU - Cao, B. AU - Du, B. AU - Shang, H. AU - Gan, J. -. H. PY - 2013 DA - 2013// TI - Clinical findings in 111 cases of influenza A (H7N9) virus infection JO - N Engl J Med VL - 368 UR - https://doi.org/10.1056/NEJMoa1305584 DO - 10.1056/NEJMoa1305584 ID - Gao2013 ER - TY - JOUR AU - Garozzo, A. AU - Tempera, G. AU - Ungheri, D. AU - Timpanaro, R. AU - Castro, A. PY - 2007 DA - 2007// TI - N-acetylcysteine synergizes with oseltamivir in protecting mice from lethal influenza infection JO - Int J Immunopathol Pharmacol VL - 20 UR - https://doi.org/10.1177/039463200702000215 DO - 10.1177/039463200702000215 ID - Garozzo2007 ER - TY - STD TI - Cheng RZ, Shi H, Yanagisawa A, Levy T, Saul A. early large dose intravenous vitamin C is the treatment of choice for 2019-nCov pneumonia. ID - ref83 ER - TY - JOUR AU - Liu, Y. AU - Yang, Y. AU - Zhang, C. AU - Huang, F. AU - Wang, F. AU - Yuan, J. PY - 2020 DA - 2020// TI - Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury JO - Sci China Life Sci. VL - 1 ID - Liu2020 ER - TY - JOUR AU - Liu, Z. AU - Guo, Z. AU - Wang, G. AU - Zhang, D. AU - He, H. AU - Li, G. PY - 2009 DA - 2009// TI - Evaluation of the efficacy and safety of a statin/caffeine combination against H5N1, H3N2 and H1N1 virus infection in BALB/c mice JO - Eur J Pharm Sci VL - 38 UR - https://doi.org/10.1016/j.ejps.2009.07.004 DO - 10.1016/j.ejps.2009.07.004 ID - Liu2009 ER - TY - JOUR AU - Humphreys, I. R. AU - Walzl, G. AU - Edwards, L. AU - Rae, A. AU - Hill, S. AU - Hussell, T. PY - 2003 DA - 2003// TI - A critical role for OX40 in T cell–mediated immunopathology during lung viral infection JO - J Exp Med VL - 198 UR - https://doi.org/10.1084/jem.20030351 DO - 10.1084/jem.20030351 ID - Humphreys2003 ER - TY - JOUR AU - Zarogoulidis, P. AU - Papanas, N. AU - Kioumis, I. AU - Chatzaki, E. AU - Maltezos, E. AU - Zarogoulidis, K. PY - 2012 DA - 2012// TI - Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases JO - Eur J Clin Pharmacol VL - 68 UR - https://doi.org/10.1007/s00228-011-1161-x DO - 10.1007/s00228-011-1161-x ID - Zarogoulidis2012 ER - TY - STD TI - Zhang J, Zhou L, Yang Y, Peng W, Wang W, Chen X. Therapeutic and triage strategies for 2019 novel coronavirus disease in fever clinics. Lancet Respir Med. 2020. ID - ref88 ER - TY - JOUR AU - Liu, Q. AU - Lu, L. AU - Hua, M. AU - Xu, Y. AU - Xiong, H. AU - Hou, W. PY - 2013 DA - 2013// TI - Jiawei-Yupingfeng-Tang, a Chinese herbal formula, inhibits respiratory viral infections in vitro and in vivo JO - J Ethnopharmacol VL - 150 UR - https://doi.org/10.1016/j.jep.2013.08.056 DO - 10.1016/j.jep.2013.08.056 ID - Liu2013 ER - TY - JOUR AU - Hou, J. AU - Liu, Y. AU - Liu, Y. AU - Shao, Y. PY - 2012 DA - 2012// TI - The MSHA strain of Pseudomonas aeruginosa activated TLR pathway and enhanced HIV-1 DNA vaccine immunoreactivity JO - PLoS ONE VL - 7 UR - https://doi.org/10.1371/journal.pone.0047724 DO - 10.1371/journal.pone.0047724 ID - Hou2012 ER - TY - JOUR AU - Zhang, W. AU - Sun, J. AU - Shen, X. AU - Xue, Y. AU - Yuan, S. AU - Wang, X. PY - 2019 DA - 2019// TI - Effect of PA-MSAH preprocessing on the expression of TLR-4-NF-κB pathway and inflammatory factors in the intestinal tract of rats with septic shock JO - Exp Ther Med VL - 17 ID - Zhang2019 ER - TY - STD TI - The CIICI, press SCIOha, traditional cotiro, treatment Cmitpa, drugs. OC-AE. 2020. ID - ref92 ER - TY - STD TI - of XITd, the tCmaei, treatment of novel coronary pneumonia t, propose tmatd, Chinese a-ppot, Medicine. 2020. ID - ref93 ER - TY - JOUR AU - Zhou, Q. AU - Chen, V. AU - Shannon, C. P. AU - Wei, X. -. S. AU - Xiang, X. AU - Wang, X. PY - 2020 DA - 2020// TI - Interferon-α2b Treatment for COVID-19 JO - Front Immunol VL - 11 UR - https://doi.org/10.3389/fimmu.2020.01061 DO - 10.3389/fimmu.2020.01061 ID - Zhou2020 ER - TY - JOUR AU - Mulangu, S. AU - Dodd, L. E. AU - Davey, R. T. AU - Tshiani Mbaya, O. AU - Proschan, M. AU - Mukadi, D. PY - 2019 DA - 2019// TI - A randomized, controlled trial of Ebola virus disease therapeutics JO - N Engl J Med VL - 381 UR - https://doi.org/10.1056/NEJMoa1910993 DO - 10.1056/NEJMoa1910993 ID - Mulangu2019 ER - TY - JOUR AU - Shen, C. AU - Wang, Z. AU - Zhao, F. AU - Yang, Y. AU - Li, J. AU - Yuan, J. PY - 2020 DA - 2020// TI - Treatment of 5 critically ill patients with COVID-19 with convalescent plasma JO - JAMA VL - 323 UR - https://doi.org/10.1001/jama.2020.4783 DO - 10.1001/jama.2020.4783 ID - Shen2020 ER - TY - JOUR AU - Xia, S. AU - Yan, L. AU - Xu, W. AU - Agrawal, A. S. AU - Algaissi, A. AU - Tseng, C. T. K. PY - 2019 DA - 2019// TI - A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike JO - Sci Adv. VL - 5 UR - https://doi.org/10.1126/sciadv.aav4580 DO - 10.1126/sciadv.aav4580 ID - Xia2019 ER - TY - JOUR AU - Coleman, C. M. AU - Sisk, J. M. AU - Mingo, R. M. AU - Nelson, E. A. AU - White, J. M. AU - Frieman, M. B. PY - 2016 DA - 2016// TI - Abelson kinase inhibitors are potent inhibitors of severe acute respiratory syndrome coronavirus and middle east respiratory syndrome coronavirus fusion JO - J Virol VL - 90 UR - https://doi.org/10.1128/JVI.01429-16 DO - 10.1128/JVI.01429-16 ID - Coleman2016 ER - TY - STD TI - Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020:1–3. ID - ref99 ER - TY - JOUR AU - Ito, K. AU - Yotsuyanagi, H. AU - Sugiyama, M. AU - Yatsuhashi, H. AU - Karino, Y. AU - Takikawa, Y. PY - 2016 DA - 2016// TI - Geographic distribution and characteristics of genotype A hepatitis B virus infection in acute and chronic hepatitis B patients in Japan JO - J Gastroenterol Hepatol VL - 31 UR - https://doi.org/10.1111/jgh.13030 DO - 10.1111/jgh.13030 ID - Ito2016 ER - TY - JOUR AU - Falzarano, D. AU - Wit, E. AU - Rasmussen, A. L. AU - Feldmann, F. AU - Okumura, A. AU - Scott, D. P. PY - 2013 DA - 2013// TI - Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV–infected rhesus macaques JO - Nat Med VL - 19 UR - https://doi.org/10.1038/nm.3362 DO - 10.1038/nm.3362 ID - Falzarano2013 ER - TY - JOUR AU - Chan, J. F. AU - Chan, K. -. H. AU - Kao, R. Y. AU - To, K. K. AU - Zheng, B. -. J. AU - Li, C. P. PY - 2013 DA - 2013// TI - Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus JO - J Infect VL - 67 UR - https://doi.org/10.1016/j.jinf.2013.09.029 DO - 10.1016/j.jinf.2013.09.029 ID - Chan2013 ER - TY - JOUR AU - Kim, U. J. AU - Won, E. -. J. AU - Kee, S. -. J. AU - Jung, S. -. I. AU - Jang, H. -. C. PY - 2016 DA - 2016// TI - Case report combination therapy with lopinavir/ritonavir, ribavirin and interferon-α for Middle East respiratory syndrome JO - Antiviral Ther VL - 21 UR - https://doi.org/10.3851/IMP3002 DO - 10.3851/IMP3002 ID - Kim2016 ER - TY - JOUR AU - Wilde, A. H. AU - Jochmans, D. AU - Posthuma, C. C. AU - Zevenhoven-Dobbe, J. C. AU - Nieuwkoop, S. AU - Bestebroer, T. M. PY - 2014 DA - 2014// TI - Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture JO - Antimicrob Agents Chemother VL - 58 UR - https://doi.org/10.1128/AAC.03011-14 DO - 10.1128/AAC.03011-14 ID - Wilde2014 ER - TY - JOUR AU - Madrid, P. B. AU - Chopra, S. AU - Manger, I. D. AU - Gilfillan, L. AU - Keepers, T. R. AU - Shurtleff, A. C. PY - 2013 DA - 2013// TI - A systematic screen of FDA-approved drugs for inhibitors of biological threat agents JO - PloS one VL - 8 UR - https://doi.org/10.1371/journal.pone.0060579 DO - 10.1371/journal.pone.0060579 ID - Madrid2013 ER - TY - JOUR AU - Barnard, D. L. AU - Day, C. W. AU - Bailey, K. AU - Heiner, M. AU - Montgomery, R. AU - Lauridsen, L. PY - 2006 DA - 2006// TI - Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice JO - Antiviral Chem Chemother VL - 17 UR - https://doi.org/10.1177/095632020601700505 DO - 10.1177/095632020601700505 ID - Barnard2006 ER - TY - JOUR AU - Rossignol, J. -. F. PY - 2014 DA - 2014// TI - Nitazoxanide: a first-in-class broad-spectrum antiviral agent JO - Antiviral Res VL - 110 UR - https://doi.org/10.1016/j.antiviral.2014.07.014 DO - 10.1016/j.antiviral.2014.07.014 ID - Rossignol2014 ER - TY - JOUR AU - Ahmed-Belkacem, A. AU - Colliandre, L. AU - Ahnou, N. AU - Nevers, Q. AU - Gelin, M. AU - Bessin, Y. PY - 2016 DA - 2016// TI - Fragment-based discovery of a new family of non-peptidic small-molecule cyclophilin inhibitors with potent antiviral activities JO - Nat Commun VL - 7 UR - https://doi.org/10.1038/ncomms12777 DO - 10.1038/ncomms12777 ID - Ahmed-Belkacem2016 ER - TY - JOUR AU - Agostini, M. L. AU - Andres, E. L. AU - Sims, A. C. AU - Graham, R. L. AU - Sheahan, T. P. AU - Lu, X. PY - 2018 DA - 2018// TI - Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease JO - MBio VL - 9 UR - https://doi.org/10.1128/mBio.00221-18 DO - 10.1128/mBio.00221-18 ID - Agostini2018 ER - TY - JOUR AU - Sheahan, T. P. AU - Sims, A. C. AU - Graham, R. L. AU - Menachery, V. D. AU - Gralinski, L. E. AU - Case, J. B. PY - 2017 DA - 2017// TI - Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses JO - Sci Transl Med VL - 9 UR - https://doi.org/10.1126/scitranslmed.aal3653 DO - 10.1126/scitranslmed.aal3653 ID - Sheahan2017 ER - TY - JOUR AU - Arabi, Y. M. AU - Alothman, A. AU - Balkhy, H. H. AU - Al-Dawood, A. AU - AlJohani, S. AU - Al Harbi, S. PY - 2018 DA - 2018// TI - Treatment of Middle East respiratory syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial JO - Trials VL - 19 UR - https://doi.org/10.1186/s13063-017-2427-0 DO - 10.1186/s13063-017-2427-0 ID - Arabi2018 ER -